ADR-12736; No of Pages 14

Advanced Drug Delivery Reviews xxx (2015) xxx-xxx



Contents lists available at ScienceDirect

Advanced Drug Delivery Reviews

journal homepage: www.elsevier.com/locate/addr



Mucoadhesive and thermogelling systems for vaginal drug delivery[☆]

Carla M. Caramella *, Silvia Rossi, Franca Ferrari, Maria Cristina Bonferoni, Giuseppina Sandri

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy

ARTICLE INFO

Available online xxxx

Keywords:

24 26

Vaginal mucosa Vaginal secretions

10 Mucoadhesive formulations

Methods for mucoadhesion testing 11

In situ gel forming systems

13 Methods for thermogelling testing

ABSTRACT

This review focuses on two formulation approaches, mucoadhesion and thermogelling, intended for prolonging 14 residence time on vaginal mucosa of medical devices or drug delivery systems, thus improving their efficacy. The 15 review, after a brief description of the vaginal environment and, in particular, of the vaginal secretions that 16 strongly affect in vivo performance of vaginal formulations, deals with the above delivery systems. As for 17 mucoadhesive systems, conventional formulations (gels, tablets, suppositories and emulsions) and novel drug 18 delivery systems (micro-, nano-particles) intended for vaginal administration to achieve either local or systemic 19 effect are reviewed. As for thermogelling systems, poly(ethylene oxide-propylene oxide-ethylene oxide) 20 copolymer-based and chitosan-based formulations are discussed as thermogelling systems. The methods 21 employed for functional characterization of both mucoadhesive and thermogelling drug delivery systems are 22 also briefly described.

© 2015 Published by Elsevier B.V.

Contents

1.	introduction
2.	Vaginal environment
3.	Mucoadhesive vaginal drug delivery systems
	3.1. Gels
	3.2. Tablets
	3.3. Suppositories/pessaries
	3.4. Emulsion-type formulations
	3.5. Microparticulate systems
	3.6. Nanoparticulate systems
	3.7. Methods for mucoadhesion testing
	3.7.1. Bulk methods
	3.7.2. Molecular scale methods
4.	Thermogelling vaginal drug delivery systems
	4.1. EO _a -PO _b -EO _a copolymer-based gelling systems
	4.2. Chitosan-based thermogelling systems
	4.3. Methods for thermogelling testing
	4.3.1. Gelation temperature (Tgel)
	4.3.2. Gelation time
	4.3.3. Mechanical and rheological properties of gel formed
5.	Biocompatibility and tolerability of excipients
6.	Conclusive remarks
Refe	erences

53

This review is part of the Advanced Drug Delivery Reviews theme issue on "Vaginal Drug Delivery"

1. Introduction

The vaginal lumen is the site of various pathologies such as vaginitis 55 caused by bacteria, fungi, protozoa or virus and has been traditionally 56 employed for the delivery of antimicrobial and antiviral drugs. Recently, 57 the vagina has been exploited as a possible administration route, in 58

http://dx.doi.org/10.1016/j.addr.2015.02.001 0169-409X/© 2015 Published by Elsevier B.V.

Please cite this article as: C.M. Caramella, et al., Mucoadhesive and thermogelling systems for vaginal drug delivery, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2015.02.001

Corresponding author. Tel.: +39 0382 987385; fax: +39 0382 422975. E-mail address: carla.caramella@unipv.it (C.M. Caramella).

79

80

81

117

118

119

120

alternative to the parenteral one, for the delivery of drugs, endowed with systemic effects, that cannot be profitably administered *per os* due to hepatic or gastrointestinal degradation or to the induction of side-effects in the gastrointestinal tract [1].

A drawback of such a route is represented by the physiological removal mechanisms, which are active in the vaginal lumen and are responsible for a scarce residence time of conventional formulations at the action/absorption site, causing an erratic drug distribution onto the mucosa.

Two are the main approaches proposed in the literature to withstand the abovementioned problems: one is represented by mucoadhesive formulations able to prolong drug permanence into the vaginal cavity thanks to the formation of physical and chemical bonds with the mucosa, the other is constituted by thermogelling liquid systems that are subjected to a sol–gel transition upon vaginal administration. Both approaches will be discussed in the review after a brief description of the vaginal environment, with particular regard to the vaginal secretions, that strongly affect *in vivo* performance of vaginal formulations. The methods employed for the functional characterization of both mucoadhesive and thermogelling drug delivery systems will also be described.

2. Vaginal environment

Vaginal epithelium is uncornified and pluristratified and its thickness (200–300 µm) is strongly dependent on age and hormonal levels, especially estrogens. Although it is considered a mucosa, it lacks goblet cells. Vaginal surface is anyway lined and protected by cervical mucus [2]. Besides cervical mucus, endometrial and tubal fluids and vaginal transudate, Bartholin's and Skenes's gland secretions contribute to vaginal fluid amount and composition. An exhaustive survey of the literature [3] suggests a production of vaginal fluid of about 6 g/day, and a volume present in the vagina of approximately 0.5–0.75 ml. Such compounds as lactic acid, acetic acid, glycerol, urea, and glucose are present in significant concentrations in vaginal fluids. Glycogen, which is present in large amount, is a substrate of microbial and enzymatic processes that result in the production of lactic acid, whose concentration is estimated between 3 and 5 g/l, and that contributes to maintain the vaginal pH to slightly acidic values, usually in the range 4–4.5 [3].

Mucus production varies with hormonal changes, with higher rate occurring during the ovulatory phase. Mucus production rate decreases to approximately 50% and 30% during the follicular and luteal phases, respectively [2].

Even the characteristics of cervical mucus are variable according to the different phases of the menstrual cycle. During the first half of the cycle, when estrogen exposure predominates, mucus is thinner and easily penetrable, while it is produced in lower amount and is thicker in consistence in the second part of the cycle due to progesterone effect. The use of contraceptive hormones increases mucus viscosity. Modifications of vaginal flora occurring in bacterial vaginosis reduce mucus viscosity compared to women with normal flora. The main representative microorganisms of vaginal flora belongs to *Lactobacillus* spp., which are responsible for the relatively low pH of vaginal environment [4–6].

Amount and composition of vaginal fluids can however change according to sexual stimulation, that strongly increases their volume and can also affect sodium and chloride concentration.

Quite important changes occur during menopause. In this condition, the epithelium becomes thin and atrophic. The changes in hormonal levels are responsible for the decrease in vaginal fluids and glycogen concentration, so that the environment becomes hostile to the protective lactobacilli that are responsible for lactic acid production and, as a consequence, vaginal pH increases. The environment faced by drug delivery systems can therefore vary depending on hormonal changes, but also on sexual intercourses or pathological conditions, with possible consequences in their performance.

3. Mucoadhesive vaginal drug delivery systems

Mucoadhesion is an attractive interaction that involves a pharma- 123 ceutical dosage form and either secreted mucus or a mucosal membrane 124 [7]. The main components of secreted mucus are soluble mucins. These 125 are highly glycosylated glycoproteins consisting of about 500 kDa sub- 126 units jointed by disulfide bridges to give large structures that entrap 127 high amount of water to give a viscoelastic protective layer over the mu- 128 cosa surface. Mucoadhesive properties allow better contact of the for- 129 mulation with the vaginal surface and longer residence times. In most 130 cases mucoadhesion is imparted to a formulation by the employment 131 of polymeric excipients. The mechanisms of mucoadhesion involve 132 firstly a contact stage, in which hydration, wetting and spreading are 133 the most important steps, and subsequently a consolidation stage, that 134 involves the strengthening of polymer-mucin joint, thanks to the interpenetration of the polymer chains into the mucus layer and the occur- 136 rence of polymer-mucin bonding (mainly weak van der Waal and 137 hydrogen bonds or electrostatic interactions) [7]. According to these 138 mechanisms, polymers with promising mucoadhesion properties are 139 those having high number of functional groups, for example hydroxyl 140 groups or unionized carboxylate groups. Molecular weight should be 141 not so high to impair hydration and chain entanglement with mucins 142 but not so low to give poor cohesion. Flexibility is important to improve 143 interpenetration with mucus. Ionizable groups can help mucoadhesion 144 if they are able to determine electrostatic interactions in the vaginal 145 environment with the anionic moieties of mucins [1,8]. Hereafter the 146 different types of vaginal mucoadhesive formulations reported in liter- 147 ature are discussed.

3.1. Gels 149

Gels are well accepted products, used for vaginal applications of var- 150 ious drugs/actives endowed with moisturizing and lubrication effect, 151 physiological pH restoring effect, contraceptive, labor inducer and mi- 152 crobicide activity [9,10].

The mucoadhesive polymers proposed in the literature and used 154 in commercial formulations for vaginal application are numerous. 155 Among the most common polyacrylic acid derivatives, such as carbomer 156 and polycarbophil, cellulose derivatives, chitosan and its derivatives, 157 hyaluronic acid, alginate, carrageenan and sulphated polysaccharides, 158 and gums are listed [4]. 159

Thanks to the high content in water that characterizes these prepa- 160 rations, gels based on mucoadhesive polymers, without addition of 161 drugs, are proposed for moisturization of the vagina in cases of vaginal 162 dryness, experienced especially during menopause, and for lubrication 163 to facilitate or enhance sexual intercourse [11,12].

An example of this kind of application of vaginal gels is represented by 165 some polycarbophil gels that form the basis of well-consolidated 166 marketed products (Replens®, Miphil®), and by a hydroxyethylcellulose 167 (HEC) based product (K-Y® jelly), that is commercialized as lubricant. 168

Other products, more specifically intended to buffer the vagina environment with the aim of restoring the physiological pH against vaginal infections, have been developed. The buffering capacity of polycarbophil 171
has been demonstrated capable of normalizing vaginal pH during the
menopause [13] and in cases of bacterial vaginosis [14]. An acid buffering 173
bioadhesive vaginal gel was based on guar gum, xanthan gum (XG) and 174
hydroxypropylmethylcellulose (HPMC K4M) combination, associated 175
with monosodium citrate as buffering agent to provide acidic pH (4.4). 176
Clotrimazole (CTZ) (antifungal), metronidazole (MTZ) (antiprotozoal as 177
well as antibacterial) and Lactobacillus acidophilus was added to treat 178
mixed vaginal infections [15].

Mucoadhesive chitosan (CS) lactate gels, based on medium (AM) 180 and high (FH) chitosan viscosity grades, were developed for the con- 181 trolled release of lactic acid onto vaginal mucosa. CS medium molecular 182 weight showed better mucoadhesive properties, likely due to the less 183 rigid structure of the gel. A full factorial design evidenced an interaction 184

Download English Version:

https://daneshyari.com/en/article/8402776

Download Persian Version:

https://daneshyari.com/article/8402776

<u>Daneshyari.com</u>